In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Standard Diagnostics Inc.

Division of Abbott Laboratories Inc.
www.standardia.com

Latest From Standard Diagnostics Inc.

In Vitro Diagnostics: The Quest For Growth

This article first appeared in Medtech Insight, October 2010.
Medical Device

In Vitro Diagnostics: The Quest for Growth

The global economic downturn has put pressure on large, consumer-based in vitro diagnostic markets, such as diabetes glucose-testing, driving down sales, pricing, and profits. As a result, the IVD industry is actively seeking out higher growth opportunities to offset this impact-and it is finding solutions in several areas, branching into underserved emerging markets like China and India and targeting higher-growth clinical segments such as cancer, women's health, and infectious disease. But perhaps the biggest opportunity for future growth lies in the field of molecular diagnostics, particularly products that address the move toward more personalized care. Suppliers well positioned to take advantage of this opportunity are likely to experience strong growth ahead.
Medical Device Platform Technologies

Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q1 2010

Highlights from the Q1 2010 review of medical device and in vitro diagnostics/research dealmaking: Medical device financings raised $609 million, the lowest since 2009's opening quarter brought in $521 million. More than half of Q1's total dollars came from VC funding with late-stage rounds garning the most. The largest financing was Mindray Medical's $151 million follow-on offering. Seven private companies involved with biomaterials companies were heavy hitters, together accounting for 14% of Q1 2010's financing dollars. There wasn't much M&A activity with just 10 deals pulling in $1.4 billion, the lowest quarter since Q2 2009's $794 million take, however, four transactions did top the $100 million mark. Financing for the in vitro diagnostics/research segment was also disappointing: only $144 million was raised, less than half of what these industries pulled in during Q4 2009 and was way down from 2009's $522 million opening quarter. Conversely, M&A activity was up. Even without counting Merck KGAA's massive $7 billion-plus takeover of research tools company Millipore Corp., the aggregate of the quarter's seven other M&A's ($729 million) still well exceeded that of the closing quarter of 2009, thanks to multiple deals reaching $100 million or more.
Medical Device
See All

Company Information

  • Industry
  • In Vitro Diagnostics
    • Biosensors
    • Chemistry, Immunoassay
    • Glucose Testing
    • Urine-based Testing
  • Medical Devices
    • Monitoring Equipment & Devices
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • South Korea
  • Parent & Subsidiaries
  • Abbott Laboratories Inc.
  • Senior Management
  • Young Shik Cho, PhD, Pres. & CEO
  • Contact Info
  • Standard Diagnostics Inc.
    Phone: (82)
    156-68 Hagal-dong, Giheung-gu
    Yongsi-si
    Kyonggi, 446-930
    South Korea
Advertisement
Advertisement
UsernamePublicRestriction

Register